Pharmaceutical giant Eli Lilly (LLY) is lowering the price of its blockbuster weight-loss drug Zepbound on its direct-to-consumer website called LillyDirect.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Effective immediately, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound on LillyDirect, depending on the dosage, down from a previous cost of $349 to $499 a month.
The announcement comes weeks after U.S. President Donald Trump reached a deal with Eli Lilly to make its weight-loss drugs easier for Americans to afford.
Cash-paying patients with a valid prescription can now purchase a starting dose of Zepbound for as low as $299 per month on LillyDirect. They can also access the next dose, 5 milligrams, for $399 a month and all other doses for $449 per month. Zepbound carries a list price of $1,086 per month.
Making Medications More Affordable
The high price point of Eli Lilly’s leading weight-loss drug, and spotty insurance coverage for it, have proven to be barriers to access for many Americans. After meeting with President Trump, Eli Lilly agreed to make its weight-loss drugs easier for Americans to access and afford.
Eli Lilly has also agreed to lower the prices the U.S. federal government pays for the weight-loss drugs in exchange for coverage under Medicare and Medicaid plans. Eli Lilly has also offered discounted prices for Zepbound on the U.S. government’s new direct-to-consumer website called TrumpRx.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 20 Wall Street analysts. That rating is based on 18 Buy and two Hold recommendations issued in the last three months. The average LLY price target of $1,035.22 implies 5.98% downside from current levels.
